Company / Return on Assets (ROA)
ENANTA PHARMACEUTICALS INC Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-47.7%
FY2025
5-year range
-47.7% / 10.6%
FY2021-FY2025
Trend
-47.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) has declined for 5 consecutive years, from 14.8% in FY2020 to -47.7% in FY2025.
Based on SEC 10-K filings.
-47.7% in FY2025 with a 5-year CAGR of -62.5%.
Declined from -17.1% to -47.7% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -38.0pp
- 5-Year Change
- -62.5pp
- 10-Year Change
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's return on assets (roa) has declined for 5 consecutive years.
- In FY2025, return on assets (roa) decreased 47.4% year-over-year.
- Peak return on assets (roa) was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -47.7% | -47.4% |
| FY2024 | -32.3% | -89.2% |
| FY2023 | -17.1% | -77.5% |
| FY2022 | -9.6% | -191.1% |
| FY2021 | 10.6% | -28.6% |
| FY2020 | 14.8% | +308.8% |
| FY2019 | 3.6% | -30.8% |
| FY2018 | 5.2% | -78.4% |
| FY2017 | 24.2% | +97.5% |
| FY2016 | 12.2% | +213.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026